To investigate how NR2F1 may lead to targeted therapy tolerance, we performed bulk RNA-Seq and gene set enrichment analysis (GSEA) on melanoma cells with or without NR2F1 overexpression that were treated with BRAFi + MEKi. The gene discussed is NR2F1; the disease is melanoma.